Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness (PALACE)

This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

38

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35222
    • California
      • Los Angeles, California, Forenede Stater, 90035
        • University of California, Los Angeles CARE Center (Site ID: 601)
        • Kontakt:
      • San Diego, California, Forenede Stater, 92103
        • UCSD Antiviral Research Center (Site ID: 701)
        • Kontakt:
      • San Francisco, California, Forenede Stater, 94110
        • University of California, San Francisco (Site ID: 801)
        • Kontakt:
      • Torrance, California, Forenede Stater, 90502-2052
        • Harbor University of California Los Angeles Center (Site ID: 603)
        • Kontakt:
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20032
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • Northwestern University (Site ID: 2701)
        • Kontakt:
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21287
        • Johns Hopkins University (Site ID: 201)
        • Kontakt:
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Massachusetts General Hospital (Site ID: 101)
        • Kontakt:
      • Boston, Massachusetts, Forenede Stater, 02115
        • Brigham and Women's Hospital Therapeutics (BWH TCRS) (Site ID: 107)
        • Kontakt:
    • New Jersey
      • Newark, New Jersey, Forenede Stater, 07103
        • New Jersey Medical School Clinical Research Center (Site ID: 31786)
        • Kontakt:
    • New York
      • New York, New York, Forenede Stater, 10010
        • Weill Cornell Chelsea (Site ID: 7804)
        • Kontakt:
      • New York, New York, Forenede Stater, 10010
        • Weill Cornell Uptown (Site ID: 7803)
        • Kontakt:
      • New York, New York, Forenede Stater, 10032
        • Columbia Physicians & Surgeons (P&S) (Site ID: 30329)
        • Kontakt:
    • North Carolina
      • Chapel Hill, North Carolina, Forenede Stater, 27599-7215
        • Chapel Hill (Site ID: 3201)
        • Kontakt:
      • Greensboro, North Carolina, Forenede Stater, 27401-1020
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45267-0405
        • Cincinnati Clinical Research Site (Site ID: 2401)
        • Kontakt:
      • Cleveland, Ohio, Forenede Stater, 44106
      • Columbus, Ohio, Forenede Stater, 43210
        • Ohio State University (Site ID: 2301)
        • Kontakt:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forenede Stater, 15213
        • University of Pittsburgh (Site ID: 1001)
        • Kontakt:
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37204
        • Vanderbilt Therapeutics (VT) (Site ID: 3652)
        • Kontakt:
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • Houston Advancing Research Team (Site ID: 31473)
        • Kontakt:
    • Washington
      • Seattle, Washington, Forenede Stater, 98104
        • University of Washington Positive Research (Site ID: 1401)
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Documented HIV-1 infection

  • Prior antiretroviral therapy (ART) experience, including having first been prescribed ART at least 24 weeks prior to enrollment and self-report of prior oral ART use

  • HIV-1 RNA >1000 copies/mL within 60 days prior to study entry

  • Evidence of non-adherence to ART, including virologic failure, poor virologic response, or loss to clinical follow-up with ART non-use/non-adherence

  • At least one reason why NNRTI-based ART is clinically inappropriate, including documented or suspected rilpivirine resistance or prior rilpivirine intolerance

  • Adequate laboratory parameters within 60 days prior to study entry:

    • Absolute neutrophil count >600/mm3
    • Hemoglobin ≥7.0 g/dL
    • Platelet count >50,000/μL
    • AST and ALT ≤3 × upper limit of normal
    • Estimated glomerular filtration rate >15 mL/min/1.73 m²
  • For participants of childbearing potential, negative pregnancy test at screening and within 24 hours prior to study entry

  • Ability and willingness to provide informed consent

  • Connected to a medical clinic with access to HIV care and antiretroviral therapy

Exclusion Criteria:

  • Documented integrase strand transfer inhibitor (INSTI) resistance-associated mutations that may compromise cabotegravir activity
  • Active hepatitis B infection, defined as positive hepatitis B surface antigen or detectable hepatitis B virus DNA
  • Child-Pugh Class C cirrhosis
  • No suitable injection site for cabotegravir administration due to implants, tattoos, or skin conditions interfering with injection site assessment
  • Prior use of lenacapavir
  • Receipt of HIV immunotherapeutic vaccines or HIV monoclonal antibodies within 6 months prior to study entry
  • Serious medical or psychiatric condition
  • Use of prohibited concomitant medications with lenacapavir or cabotegravir within 30 days prior to study entry
  • Current pregnancy or breastfeeding
  • Known allergy, hypersensitivity, or intolerance to cabotegravir, lenacapavir, or formulation components

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Long-Acting Lenacapavir Plus Long-Acting Cabotegravir

Long-acting subcutaneous lenacapavir administered every 24 weeks with oral loading doses at treatment initiation.

Long-acting intramuscular cabotegravir administered every 8 weeks following initiation doses.

Oral antiretroviral therapy provided as bridge therapy during interruptions or delays in long-acting treatment.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Proportion of participants achieving and maintaining viral suppression (no confirmed virologic failure) while receiving long-acting lenacapavir plus cabotegravir
Tidsramme: Baseline through Week 48
Baseline through Week 48

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tidsramme: Week 48
Week 48
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tidsramme: Week 48
Week 48
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tidsramme: Week 48
Week 48
Proportion of participants with Grade 3 or higher adverse events related to long-acting lenacapavir plus cabotegravir
Tidsramme: Baseline through Week 96
Baseline through Week 96
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir due to adverse events or intolerance
Tidsramme: Baseline through Week 96
Baseline through Week 96
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure on long-acting lenacapavir plus cabotegravir
Tidsramme: Baseline through Week 96
Baseline through Week 96
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tidsramme: Week 96
Week 96
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tidsramme: Week 96
Week 96
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tidsramme: Week 96
Week 96
Percentage of on-time long-acting injections
Tidsramme: Through Week 48 and through Week 96
Through Week 48 and through Week 96
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir
Tidsramme: Baseline through Week 48 and through Week 96
Baseline through Week 48 and through Week 96
Plasma trough concentrations of lenacapavir and cabotegravir
Tidsramme: Through Week 48 and through Week 96
Through Week 48 and through Week 96
Change in CD4 cell count from baseline
Tidsramme: Week 48 and Week 96
Week 48 and Week 96
Participant-reported treatment satisfaction
Tidsramme: Week 48 and Week 96

HIV Treatment Satisfaction Questionnaire assesses participant satisfaction with the long-acting treatment.

Week 48 and Week 96
Change in quality-of-life scores from baseline
Tidsramme: Week 48 and Week 96

Quality of life will be assessed using the Veterans Rand 12-item Health Survey (VR-12). Scores range from 0 to 100, with higher scores indicating better health-related quality of life.

Week 48 and Week 96
Change in Patient Health Questionnaire-9 (PHQ-9) scores from baseline
Tidsramme: Week 48 and Week 96

Symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.

Week 48 and Week 96
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure among participants not requiring oral bridge therapy
Tidsramme: Baseline through Week 48
Baseline through Week 48
Proportion of participants without oral bridge therapy with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tidsramme: Week 48
Week 48
Proportion of participants without oral bridge therapy with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tidsramme: Week 48
Week 48
Proportion of participants without oral bridge therapy with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tidsramme: Week 48
Week 48

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. februar 2028

Primær færdiggørelse (Anslået)

31. august 2029

Studieafslutning (Anslået)

26. oktober 2030

Datoer for studieregistrering

Først indsendt

10. november 2026

Først indsendt, der opfyldte QC-kriterier

10. november 2026

Først opslået (Faktiske)

16. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • A5431
  • 39159 (Anden identifikator: DAIDS-ES ID)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Individual participant data that underlie results in the publication after deidentification

IPD-delingstidsramme

Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH

IPD-delingsadgangskriterier

With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.

For what types of analyses? To achieve aims in the proposal approved by the ACTG.

By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .